Anakinra vs Prednisone to Treat Gout Flare in Patients With Chronic Kidney Disease Stage 4/5 or Renal Transplantation

A phase 2 trial registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 204 participants.

Also called NCT04844814

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 204 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04844814
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Suspended (from the registry)

Technical summary

Registry record NCT04844814. Randomized; quadruple masking; primary purpose treatment. Start 2022-06-02 (actual); primary completion 2025-02-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Anakinra vs Prednisone to Treat Gout Flare in Patients With Chronic Kidney Disease Stage 4/5 or Renal Transplantation
Acronym
Ana4CKD
Condition
Gout
Condition
Renal Transplantation
Intervention (Drug)
Anakinra 100Mg/0.67Ml Inj Syringe
Intervention (Drug)
Prednisone
Intervention (Drug)
Placebo of Prednisone
Intervention (Drug)
Placebo of Anakinra
Lead sponsor
Assistance Publique - Hôpitaux de Paris (class: other)

Record details

Record id
cardio:ct-nct04844814
Content hash
c1dca5e86b09b6ae96c22a575ef951c360e6c3454658d70ad10385efa045443c